Inmune Bio, Inc. Balance Sheet
INMB|7 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 7 fiscal years. All figures from audited SEC 10-K filings.
Inmune Bio, Inc. had $32M in total assets and $32M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | $20.9M | $35.8M | $52.2M | $74.8M | $7.0M | $1.4M |
| Accounts Receivable | $4.3M | $1.2M | - | - | - | - | - |
| Current Assets | $29.9M | $22.7M | $39.9M | $64.7M | $82.6M | $24.0M | $849.3K |
| PP&E (Net) | $955.0K | - | - | - | - | - | - |
| Total Assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M | $40.7M | $17.4M |
| Current Liabilities | $8.4M | $7.2M | $18.5M | $10.9M | $4.4M | $1.8M | - |
| Total Debt | - | - | - | - | $15.0M | - | - |
| Shareholders' Equity | $32.1M | $37.3M | $60.1M | $80.2M | $38.8M | $23.6M | $18.1M |